The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Degarelix for injection [package insert].Parsippany, NJ: Ferring Pharmaceuticals; 2008.
2.
KlotzL., Boccon-GibodL., ShoreN.D.The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int.2008; 102(11): 1531–1538.
3.
GittelmanM., PommervilleP.J., PerssonB.E., JensenJ.K., OlesenT.K.A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment for prostate cancer in North America. J Urol.2008; 180(5): 1986–1992.
4.
Van PoppelH., TombalB., de la RosetteJ.J., PerssonB.E., JensenJ.K., OlesenT.K.Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker—results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol.2008; 54(4): 805–813.
MacFarlandR., EwesuedoR.B., BadelK., CalandraG.Pharmacokinetics of plerixafor (AMD3100) in volunteers with renal impairment (ASH Annual Meeting Abstracts). Blood.2007; 110(11): abstract 2878.
7.
DiPersioJ.F., MicallefI.N.M., StiffP.J.12 months report from the phase 3 study of plerixafor + G-CSF vs. placebo + G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with NHL (ASH Annual Meeting Abstracts). Blood.2008; 112(11): abstract 1136.
8.
DiPersioJ.F., StadtmauerE.A., NademaneeA.P.12 months report from a phase 3 study of plerixafor + G-CSF vs. placebo + G-CSF for mobilization of hematopoietic stem cell for autologous transplant in patients with multiple myeloma (ASH Annual Meeting Abstracts). Blood.2008; 112(11): abstract 3312.
9.
CashenA., LopezS., GaoF.A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Bone Marrow Transplant.2008; 14(11): 1253–1261.
10.
LemeryS.J., HsiehM.M., SmithA.A pilot study evaluating the CD34+ cell mobilizing activity and adverse events associated with escalating doses of AMD3100 in healthy volunteers (ASH Annual Meeting Abstracts). Blood.2007; 110(11): abstract 3278.
11.
UyG.L., RettigM.P., McFarlandK.M.Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): a phase I/II study of AMD3100 + MEC in patients with relapsed or refractory disease (ASH Annual Meeting Abstracts). Blood.2008; 112(11): abstract 1944.
12.
CalandraG., McCartyJ., McGuirkJ.AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant.2008; 41(4): 331–338.
